Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Filgrastim 14Cyclophosphamide 13Carboplatin 12Paclitaxel 8Ifosfamide 8Doxorubicin 8pembrolizumab 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6fludarabine 5Temozolomide 5Specimen Handling 5Radiotherapy 5Cisplatin 5Magnetic Resonance Spectroscopy 4Etoposide 4Docetaxel 4Amifostine 4aldesleukin 3Trastuzumab 3Taxes 3Psychiatric Rehabilitation 3Melphalan 3Fulvestrant 3Bevacizumab 3sodium thiosulfate 2pazopanib 2pamiparib 2palbociclib 2etoposide phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × resiquimod × Sarcoma × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡